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Abstract
 
CD16
 
  
 
monocytes represent 5–10% of peripheral blood monocytes in normal individuals and
are dramatically expanded in several pathological conditions including sepsis, human immuno-
deficiency virus 1 infection, and cancer. CD16
 
  
 
monocytes produce high levels of proin-
flammatory cytokines and may represent dendritic cell precursors in vivo. The mechanisms that
mediate the recruitment of CD16
 
  
 
monocytes into tissues remain unknown. Here we investi-
gate molecular mechanisms of CD16
 
  
 
monocyte trafficking and show that migration of
CD16
 
  
 
and CD16
 
  
 
monocytes is mediated by distinct combinations of adhesion molecules and
chemokine receptors. In contrast to CD16
 
  
 
monocytes, CD16
 
  
 
monocytes expressed high
CX3CR1 and CXCR4 but low CCR2 and CD62L levels and underwent efficient transendo-
thelial migration in response to fractalkine (FKN; FKN/CX3CL1) and stromal-derived fac-
tor 1
 
  
 
(CXCL12) but not monocyte chemoattractant protein 1 (CCL2). CD16
 
  
 
monocytes
arrested on cell surface–expressed FKN under flow with higher frequency compared with
CD16
 
  
 
monocytes. These results demonstrate that FKN preferentially mediates arrest and mi-
gration of CD16
 
  
 
monocytes and suggest that recruitment of this proinflammatory monocyte
subset to vessel walls via the CX3CR1-FKN pathway may contribute to vascular and tissue in-
jury during pathological conditions.
Key words: chemokines • chemokine receptors • chemotaxis • cell adhesion • inﬂammation
 
Introduction
 
Peripheral blood monocytes are a heterogeneous popula-
tion (for review see 1). In normal individuals, 90–95% of
circulating monocytes express high CD14 and CD64
(Fc
 
 
 
RI) levels, whereas 5–10% express CD16 (Fc
 
 
 
RIII;
for review see 2). Two subsets of CD16
 
  
 
monocytes can be
distinguished: CD14
 
high 
 
CD64
 
  
 
and CD14
 
low 
 
CD64
 
  
 
(1). A
dramatic increase in circulating CD16
 
  
 
monocytes has
been reported in pathologies such as sepsis, HIV-1 infec-
tion, metastatic cancer, tuberculosis, and asthma (2–4).
Compared with CD16
 
  
 
monocytes, CD16
 
  
 
monocytes
produce higher levels of TNF-
 
  
 
(3, 5) and IL-1 (3) but not
IL-10 (2), exhibit lower phagocytic activity (1), and have
higher antigen presenting capacity (1). A recent report
demonstrated that CD16
 
  
 
monocytes preferentially differ-
entiate into dendritic cells in a model of transendothelial
trafficking (6), suggesting that CD16
 
  
 
monocytes represent
dendritic cell precursors in vivo.
Although several reports have documented functional
characteristics of CD16
 
  
 
monocytes (1–6), the mechanisms
of CD16
 
  
 
monocyte recruitment into tissues remain un-
known. Monocyte chemoattractant protein 1 (MCP-1;
 
*
 
CCL2), the most potent chemokine for CD16
 
  
 
mono-
cytes, does not trigger transendothelial migration (TEM) of
CD16
 
  
 
monocytes as a consequence of low CCR2 expres-
sion (7). Furthermore, L-selectin (CD62L), which mediates
lymphocyte homing into lymph nodes (8), is expressed at
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Abbreviations used in this paper:
 
 FKN, fractalkine; HUVEC, human um-
bilical vascular endothelial cells; ICAM-1, intercellular adhesion molecule
1; iHUVEC, immortalized HUVEC; IM, index of migration; MCP-1,
monocyte chemoattractant protein 1; MIP-1
 
 
 
, macrophage inflammatory
protein 1
 
 
 
; pHUVEC, primary HUVEC; PSGL-1, P-selectin glycopro-
tein ligand 1; SDF-1
 
 
 
, stromal-derived factor 1
 
 
 
; TEM, transendothelial
migration; VCAM-1, vascular cell adhesion molecule 1; VLA-4, very late
antigen 4.T
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CD16
 
 
 
 Monocyte Trafficking
 
high levels on CD16
 
  
 
monocytes but at very low levels on
CD16
 
  
 
monocytes (9), raising the possibility that CD16
 
 
 
monocytes may not be recruited into lymph nodes.
Whether CD16
 
  
 
monocytes are recruited into nonlym-
phoid tissues via chemokines other than MCP-1 is un-
known. Recent studies demonstrate that distinct chemo-
kines trigger migration of specific monocyte subsets (for
review see 10). MCP-1 mediates CCR2
 
  
 
CD62L
 
  
 
mono-
cyte recruitment into lymph nodes under inflammatory
conditions (11), constitutive breast- and kidney-expressed
chemokine (BRAK/CXCL14) is selectively chemotactic
for prostaglandin E2–stimulated monocytes (12), and
monokine induced by IFN-
 
  
 
(MIG/CXCL9) mediates re-
cruitment of a minor CXCR3
 
  
 
monocyte subset (13).
These findings suggest distinct mechanisms for tissue-spe-
cific recruitment of monocyte subsets similar to those de-
scribed for lymphocytes (14).
Given the dramatic expansion of CD16
 
  
 
monocytes in
several pathological conditions, we sought to characterize
the mechanism of their recruitment into tissues. Here we
demonstrate that CD16
 
  
 
and CD16
 
  
 
monocytes have dis-
tinct patterns of chemotactic migration and that fractalkine
(FKN; FKN/CX3CL1) plays a key role in mediating pref-
erential arrest and migration of CD16
 
  
 
monocytes. These
results suggest that proinflammatory CD16
 
  
 
monocytes
might be preferentially recruited into anatomic sites ex-
pressing FKN and contribute to vascular and tissue injury
during pathological conditions in which this monocyte
subset is expanded.
 
Materials and Methods
 
Reagents and Antibodies.
 
Recombinant human MCP-1, mac-
rophage inflammatory protein 1
 
  
 
(MIP-1
 
 
 
), stromal-derived fac-
tor 1
 
  
 
(SDF-1
 
 
 
), FKN, TNF-
 
 
 
, and IFN-
 
  
 
were from R&D
Systems. FKN biotin was from Exalpha Biologicals Inc. The fol-
lowing antibodies were used: FITC anti-CD14, anti-CD16, anti-
CD16b, anti-CD62L, PE anti-CD33, CD56, anti–intercellular
adhesion molecule 1 (ICAM-1), and PC5 anti-CD16 mAbs
(Beckman Coulter); FITC anti-CD62E and PE anti-CCR1, anti-
CCR2, anti-CCR3, anti-CXCR5, and anti-FKN mAbs (R&D
Systems); FITC anti-CX3CR1 mAb (MBL International Corpo-
ration); FITC anti-CD3, anti-CD32, anti-CD64, PE anti-CCR5,
anti-CXCR1, anti-CXCR2, anti-CXCR4, anti–P-selectin glyco-
protein ligand 1 (PSGL-1), anti-CD18, anti-CD11a, anti-CD11b,
anti-CD11c, anti-CD49d, anti–HLA-DR, and anti–vascular cell
adhesion molecule 1 (VCAM-1) mAbs (BD Biosciences).
 
Cell Isolation.
 
PBMCs were isolated from fresh blood of
healthy volunteers by Ficoll-Paque gradient centrifugation. The
study protocol and informed consent forms were approved by
the Dana-Farber Cancer Institute Institutional Review Board.
Monocytes were isolated by negative selection using magnetic
beads (Miltenyi Biotec). The purity of the monocyte fraction was
95–98% as determined by staining with anti-CD14, anti-CD33,
anti-CD16b, and anti-CD56 mAbs and FACS
 
® 
 
analysis. CD16
 
 
 
and CD16
 
  
 
monocyte subsets were then isolated using magnetic
beads coated with anti-CD16 mAb (Miltenyi Biotec). Staining
with anti-CD14 and anti-CD16 mAbs showed 
 
 
 
95% CD16
 
 
 
monocytes in the CD16
 
  
 
fraction and 
 
 
 
80% CD16
 
  
 
monocytes
in the CD16
 
  
 
fraction.
 
FKN Binding.
 
Monocytes from whole blood and PBMCs
were stained with PE anti-CD33, PC5 anti-CD16 mAbs, and
FKN biotin (extracellular domain, 0.5 
 
 
 
g/10
 
6 
 
cells for 30 min at
4
 
 
 
C) followed by FITC streptavidin. The specificity of FKN
binding was determined by preincubation of the cells with unla-
beled FKN (extracellular domain, 1 
 
 
 
g/10
 
6 
 
cells for 10 min at
4
 
 
 
C). Fixed cells were then subjected to FACS
 
® 
 
analysis.
 
RT-PCR Detection of CX3CR1 mRNA.
 
Total RNA was
isolated using the RNeasy mini kit (QIAGEN), primed (1 
 
 
 
g)
with random hexamers (Promega), and reverse transcribed. Lim-
iting dilutions of cDNA from the RT reaction mixture were sub-
jected to PCR amplification using Taq polymerase (Invitrogen)
for 35 cycles (94
 
 
 
C for 30 s, 58
 
 
 
C for 30 s, and 72
 
 
 
C for 1 min).
The CX3CR1 primers were: 5
 
 
 
-ACT CGT CTC TGG TAA
AGT CTG -3
 
  
 
and 5
 
 
 
-GGC TTT GGC TTT CTT GTG G-3
 
 
 
.
The 
 
  
 
globin primers were: 5
 
 
 
-CAA CTT CAT CCA CGT
TCA CC-3
 
 
 
 (PCO4) and 5
 
 
 
-GAA GAG CCA AGG ACA GGT
AC-3
 
  
 
(GH2O).
 
Endothelial Cell Immortalization and Culture.
 
Primary human
umbilical vascular endothelial cells (HUVEC) were purchased
from Clonetics/BioWhittaker and immortalized with the recom-
binant retrovirus LXSN16 E6/E7 as previously described (15) to
expand their lifespan in vitro. Immortalized HUVEC (iHUVEC)
were cultured on collagen-coated flasks in EGM-MV medium
(BioWhittaker) containing 200 
 
 
 
g/ml G418.
 
Immunofluorescence Staining.
 
Primary HUVEC (pHUVEC)
and iHUVEC were cultured at confluence on fibronectin-coated
coverslips, fixed with ethanol at 
 
 
 
20
 
 
 
C, and then stained with
anti–JAM-1 (2A9; provided by C. Parkos, Emory University
School of Medicine, Atlanta, GA), anti–
 
 
 
-catenin (Research Di-
agnostics), or anti–VE-cadherin mAbs (Beckman Coulter) as pre-
viously described (16).
 
Transwell and TEM Assays.
 
Chemotaxis assays were per-
formed as previously described (7, 17). In brief, iHUVEC were
cultured on collagen-coated transwells (6.5 mm diameter and 5
 
 
 
m pore size; Corning Costar) at 2 
 
  
 
10
 
5 
 
cells/well in
EGM-MV medium for 2 d. The confluence of the monolayers
was assessed by measurement of the electrical resistance using a
Millicell
 
®
 
–ERS electrode (Millipore). Serial dilutions of chemo-
kines in DMEM containing 0.5% BSA were placed in the bottom
chamber of the transwell system. 10
 
6 
 
monocytes isolated by nega-
tive selection and stained with PC5 anti-CD16 mAb were placed
in the upper chamber and incubated for 2.5–4 h at 37
 
 
 
C. The
number of migrated CD16
 
  
 
and CD16
 
  
 
monocytes was deter-
mined by FACS
 
® 
 
analysis using Flow-Count Fluorospheres
(Beckman Coulter). The index of migration (IM) was calculated
as the ratio between the number of cells migrated in response to
chemokine and medium alone.
 
Generation of FKN-expressing HUVEC Line.
 
The FKN open
reading frame was amplified via PCR from pORF9hFractalkine
(InvivoGen), cloned into pcDNA3.1/Hygro(
 
 
 
) (Invitrogen),
and confirmed by sequencing. pcDNA3.1/Hygro(
 
 
 
)/FKN was
transfected into iHUVEC using Lipofectamine 2000 (Invitro-
gen). FKN-transfected iHUVEC were cultured in EGM-MV
medium containing 200 
 
 
 
g/ml G418 and 100 
 
 
 
g/ml hygromy-
cin and then sorted by FACS
 
® 
 
for high membrane-bound FKN
expression (FKN-HUVEC).
 
Adhesion Assay under Flow Conditions.
 
The parallel flow
chamber used in this study has been previously described (16,
18). Endothelial cells were cultured on fibronectin-coated cover-
slips and then assembled in the flow chamber. The chamber was
mounted on a phase contrast/fluorescence microscope (Nikon
Eclipse TE 300) connected to an Orca ER camera (Hamamatsu).T
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Images were acquired using MetaMorph software. Monocytes
isolated by negative selection were stained with FITC anti-CD16
mAb, suspended at 106/ml, and perfused over the endothelial
monolayers at a shear stress rate of 0.5 dynes/cm2 using a syringe
pump (Harvard Apparatus). The number of total and CD16 
monocytes arrested onto endothelial cells was determined by
counting five different microscope fields.
Online Supplemental Material. We use FACS® analysis to
demonstrate comparable expression of E-selectin and ICAM-1
on TNF- –stimulated pHUVEC and iHUVEC, and an in vitro
flow model to demonstrate firm arrest of CD16  monocytes onto
TNF- /IFN- –stimulated pHUVEC under flow. The online
supplemental figures are available at http://www.jem.org/cgi/
content/full/jem.20022156/DC1.
Results and Discussion
CD16   Monocytes Express High Levels of CX3CR1.
The expression of a large panel of chemokine receptors and
adhesion molecules was assessed on monocyte subsets. Stain-
ing with anti-CD14 and anti-CD16 mAbs distinguished
three monocyte subsets: CD14high  CD16 , CD14high
CD16 , and CD14low CD16 , representing 85.5   6.2,
3.6   1.5, and 6.7   3.0% of total monocytes, respectively
(mean   SD, n   8; Fig. 1 A), consistent with previous re-
ports (1). The high expression of HLA-DR on CD14low
CD16  monocytes, together with the absence of neutrophil
(CD16b, expressed on neutrophils but not monocytes nor
NK cells; 19), NK (CD56), and T cell (CD3) markers (Fig.
1, B and D, and unpublished data), demonstrated the mono-
cyte identity of these cells. The major CD14high CD16 
monocyte subset expressed high CCR1, CCR2, CXCR2,
CXCR4, PSGL-1, CD62L, CD18, CD11a, CD11b,
CD11c, very late antigen 4 (VLA-4), ICAM-1, CD31,
CD44, CD32, CD64, and HLA-DR, intermediate
CXCR1, and low or undetectable CCR3, CCR5,
CXCR5, and CX3CR1 levels (Fig. 1, C and D, and un-
published data). Compared with CD16   monocytes,
CD14low CD16  monocytes expressed significantly lower
levels of CCR1, CCR2, CXCR1, and CXCR2, similar
levels of CXCR4, and higher levels of CX3CR1 (Fig. 1 C).
The expression of PSGL-1 was high in both monocyte sub-
sets, whereas CD62L expression was high on CD16  mono-
cytes but low or undetectable on CD14low CD16  mono-
cytes (Fig. 1 D). The adhesion molecules CD18, CD11a,
CD11b, CD11c, VLA-4, ICAM-1, CD31, and CD44 were
expressed on 95–100% of both CD16  and CD14low CD16 
monocytes (Fig. 1 D and unpublished data). The mean fluo-
rescence intensity for CD18, CD11a, CD11c, VLA-4, and
CD31 expression was higher on CD16  monocytes as com-
pared with CD16  monocytes (unpublished data). The phe-
notype of CD14high CD16  monocytes was intermediate be-
tween that of CD14low CD16  and CD16  monocytes (Fig.
1, C and D). Similar to CD14low CD16  monocytes, a sig-
nificant decrease in CCR2, CD62L, and CD64, and in-
crease in CX3CR1 expression was observed on CD14high
CD16   compared with CD16   monocytes. CD14high
CD16  monocytes could be distinguished from the other
two monocyte subsets by high CCR5 expression (Fig. 1 C).
The pattern of CCR1, CCR2, CX3CR1, and CD62L ex-
pression on the three monocyte subsets was similar when
staining was performed on whole blood and PBMCs, indi-
cating that expression of these markers was not altered by Fi-
coll separation (unpublished data).
We further analyzed the expression of CX3CR1 mole-
cules by intracellular staining and observed high, intermedi-
ate, and low/undetectable levels of CX3CR1 expression in
CD14low CD16 , CD14high CD16 , and CD14high CD16 
monocytes, respectively (unpublished data). Moreover,
semiquantitative RT-PCR demonstrated that the level of
CX3CR1 mRNA in CD16  monocytes was more than
twofold higher compared with CD16  monocytes as deter-
mined by the CX3CR1/  globin mRNA ratio for an RT
product dilution of 1:20 (Fig. 2). CX3CR1 is the receptor
for FKN, a membrane-bound glycoprotein with a unique
CX3C chemokine domain atop an extended mucin-like
stalk that can be released from the cell surface by proteolysis
(for review see 20). We investigated whether differential
expression of CX3CR1 on monocyte subsets is associated
Figure 1. Phenotypic analysis of human monocyte subsets. (A) PBMCs
were stained with FITC anti-CD14 and PC5 anti-CD16 mAbs. Mono-
cytes were gated according to size, granularity, and CD14 expression.
Three subsets of monocytes were identified: CD14high CD16 , CD14high
CD16 , and CD14low CD16 . Results are representative of experiments
performed with cells from 20 different donors. (B) PBMCs were stained
with FITC anti-CD14, PE anti-CD56, and PC5 anti-CD16 mAbs, and
CD14  monocytes were analyzed for CD16 and CD56 expression. Re-
sults are representative of four experiments performed with cells from dif-
ferent donors. (C and D) PBMCs were stained with FITC anti-CD14,
PC5 anti-CD16, and the indicated mAbs, and the phenotype of each
monocyte subset was analyzed by flow cytometry. Values represent the
percentage of positive cells (mean   SD, n   9). *, P   0.05, Student’s t
test (CD16  vs. CD16  monocytes).T
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with differences in their ability to bind FKN. Consistent
with the levels of CX3CR1 expression, we detected low
levels of FKN binding on CD16  monocytes, whereas
CD16   monocytes, particularly CD14low  CD16   mono-
cytes from whole blood and PBMCs, specifically bound
high levels of soluble FKN (Table I). FKN binding activity
was previously demonstrated for NK cells, monocytes, and
some CD8  T cells (17). Here we demonstrate that among
circulating monocytes, high levels of CX3CR1 expression
and FKN binding are detected on a minor CD16  subset,
whereas CD16  monocytes exhibit very low CX3CR1 ex-
pression and little FKN binding. Similarly, two mono-
cyte  subsets have been identified in mouse, CCR2 
CX3CR1med CD62L  and CCR2  CX3CR1high CD62L 
(11), sharing phenotypic characteristics with human CD16 
and CD16  monocytes, respectively. Human CD16  and
mouse CCR2  CX3CR1high CD62L  monocytes do not
migrate in response to MCP-1 (7, 11), but whether they are
recruited by other chemokines is unknown.
FKN Triggers CD16  Monocyte Migration. The differen-
tial expression of chemokine receptors on monocyte subsets
suggested that distinct mechanisms may regulate their traf-
ficking. Thus, we investigated chemotactic migration of
CD16  and CD16  monocytes in response to MCP-1,
MIP-1  (CCL3), SDF-1  (CXCL12), and FKN. The ex-
pression of CD16 on monocytes rapidly decreases after sev-
eral hours in culture (5 and unpublished data). Therefore,
we stained monocytes with fluorescent anti-CD16 mAb
and followed their chemotactic migration in a transwell sys-
tem. Monocyte staining with anti-CD16 mAb had no sig-
nificant effect on the total number of migrated cells (un-
published data). The spontaneous migration of CD16 
monocytes was higher compared with that of CD16 
monocytes (17.3   3.4% vs. 9.5   3.3%, mean   SD, n  
3). In preliminary experiments, chemokine concentrations
inducing optimal migration of monocytes were determined
(e.g., 50–100 ng/ml for MCP-1, MIP-1 , and SDF-1 ,
and 1–10 ng/ml for FKN). The results presented in Fig. 3,
A and C, demonstrate that CD16  and CD16  monocytes
have distinct patterns of chemotactic migration. MCP-1,
MIP-1 , and SDF-1  induced a high IM in CD16  mono-
cytes, whereas a low IM was observed in response to FKN
(Fig. 3 A). In contrast, CD16  monocytes did not migrate
in response to MCP-1 nor MIP-1  but migrated efficiently
in response to SDF-1  and FKN with a significantly higher
IM (8.9   0.1 and 5.7   2.1, respectively) compared with
CD16  monocytes (5.5   1.2 and 2.1   0.4, respectively;
Fig. 3 A). Thus, consistent with high CX3CR1 and
CXCR4 expression, CD16  monocytes underwent prefer-
ential migration in response to FKN and SDF-1 .
To emigrate from the vasculature, chemokine-activated
leukocytes must penetrate between adjacent endothelial
cells and gain access to the underlying basement membrane
(21). Therefore, we investigated the ability of CD16  and
CD16  monocytes to cross a confluent endothelial mono-
layer in response to MCP-1, SDF-1 , and FKN. For these
studies we used iHUVEC, which formed confluent “cob-
blestone” monolayers and showed junctional staining for
VE-cadherin, JAM1,  -catenin, and CD31 similar to
pHUVEC (Fig. 3 B and unpublished data). Stimulation by
TNF-  induced comparable levels of CD62E, ICAM-1,
and VCAM-1 expression on iHUVEC and pHUVEC
(Fig. S1, available at http://www.jem.org/cgi/content/
full/jem.20022156/DC1, and unpublished data). The per-
centage of CD16  and CD16  monocytes that underwent
spontaneous TEM (0.9   0.2% and 0.3   0.1%, respec-
Figure 2. Expression of CX3CR1 mRNA in CD16  and CD16 
monocytes. Total RNA from CD16  and CD16  monocytes was reverse
transcribed and serial dilutions of the RT product were subjected to PCR
amplification using CX3CR1 and   globin primers. The optical density
of each PCR band was determined using Eagle Sight software (Strat-
agene). Results are representative of three experiments performed using
monocytes from different donors.
Table I. FKN Binding on Monocyte Subsets
Monocyte subsets
CD14high CD16  CD14high CD16  CD14low CD16 
Blood Percent positive cells 25.3   10.1 30.0   14.9 76.3   4.7a
MFI 15.5   9.2 24.5   13.4 31.0   17.0
PBMC Percent positive cells 29.0   2.8 55.0   8.5a 74.0   15.6a
MFI 14.1   1.6 29.0   1.0a 16.7   2.4a
FKN binding was analyzed on monocyte subsets after staining of fresh blood and PBMCs from the same donor. Cells were incubated with FITC
anti-CD14, PC5 anti-CD16, and FKN-biotin, and then with PE streptavidin. Values represent the percentage of cells binding FKN after subtracting
the background (i.e., the level of FKN–biotin binding that was not blocked by preincubation with unlabeled FKN) and the geometric mean
fluorescence intensity (mean   SD, n   3).
aP   0.05, Student’s t test (CD16  vs. CD16  monocytes).T
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tively, mean   SD, n   3) was dramatically reduced com-
pared with the transwell system, probably due to the strong
adherence of monocytes to endothelial cells under static
conditions (unpublished data). MCP-1 induced high TEM
of CD16  monocytes (IM 40.3   12.2), but low TEM of
CD16  monocytes (6.9   2.7, Fig. 3 C). The low TEM of
CD16  monocytes in response to MCP-1 probably reflects
migration of the CD14high CD16  subset, which expresses
intermediate levels of CCR2. Consistent with the levels of
CX3CR1 expression, FKN induced high TEM of CD16 
monocytes (IM 11.5   3.3), but little migration of CD16 
monocytes (IM 2.7   0.6, Fig. 3 C). CD16  monocytes
underwent TEM with a significantly higher IM in response
to FKN than to MCP-1 (11.5   3.3 vs. 6.9   2.7, P  
0.05; Fig. 3 C). Moreover, FKN in combination with
SDF-1  dramatically increased the TEM of CD16  mono-
cytes (IM 19.9.   0.8), but not CD16  monocytes (IM
3.8   0.4, Fig. 3 C). These results suggest that FKN and
SDF-1 , which are expressed under both constitutive and
inflammatory conditions in vivo (20, 22), may act in an ad-
ditive manner to regulate CD16  monocyte trafficking.
The TEM of CD16  monocytes in response to FKN was
lower compared with that of CD16  monocytes in re-
sponse to MCP-1 (11.5   3.3 vs. 40.3   12.2, P   0.05;
Fig. 3 C). This difference in efficiency of TEM might be a
consequence of the stronger adherence of CD16  mono-
cytes to endothelial cells compared with that of CD16 
monocytes (unpublished data). Previous studies reported
the chemotactic effect of FKN on total monocytes (17, 23).
In this study we demonstrate that FKN preferentially trig-
gers migration of CD16  monocytes.
FKN Mediates Firm Arrest of CD16  Monocytes Under
Flow. Monocyte recruitment into tissues requires
sequential and overlapping adhesion pathways includ-
ing  CD62L, PSGL-1, VCAM-1, VLA-4,  2 integrins,
ICAM-1, and CD31, and takes place under flow condi-
tions (18, 24). Consistent with previous studies (9), we de-
tected low expression of CD62L on CD16  monocytes,
which may impair their ability to migrate into lymph
nodes, as previously demonstrated for mouse CCR2 
CD62L  monocytes (11). Whether CD16  monocytes are
recruited into other peripheral tissues is unknown. The
preceding experiments demonstrated that CX3CR1 is
highly expressed on CD16  monocytes (Fig. 1 C and Ta-
ble I) and that FKN induces preferential migration of these
cells (Fig. 3, A and C). The membrane-bound form of
FKN is expressed on endothelial cells after stimulation
with inflammatory cytokines (23) and mediates monocyte
adhesion under flow conditions (25). Thus, CX3CR1
might compensate for the low expression of CD62L on
CD16  monocytes and thereby may play a critical role in
recruitment of this monocyte subset. Therefore, we inves-
tigated the adhesion of CD16  and CD16  monocytes to
FKN-expressing endothelial cells using an in vitro flow
model. Optimal FKN expression was induced by stimula-
tion of iHUVEC with TNF-  and IFN-  (ST-HUVEC),
which also induced high levels of CD62E and VCAM-1
expression (Fig. 4 A, top). A stable cell line (FKN-
HUVEC) that expresses membrane-bound FKN in the
absence of CD62E and VCAM-1 was generated (Fig. 4 A,
bottom). Monocytes were perfused over endothelial
monolayers at a flow rate of 0.5 dynes/cm2. Under these
conditions, monocytes attached to FKN-HUVEC and
ST-HUVEC, but not to unstimulated HUVEC (Fig. 4 B,
NS-HUVEC). The percentage of CD16  monocytes in
the fraction arrested onto FKN-HUVEC was 2.6-fold
higher than that in the input fraction (18.6   3.4% vs. 7  
1.3%), indicating a more efficient interaction of CD16 
monocytes with membrane-bound FKN compared with
CD16  monocytes (Fig. 4 C). The percentage of CD16 
monocytes arrested onto ST-HUVEC was slightly higher
than that in the input fraction (8.6   0.3% vs. 7.1   1.3%;
Figure 3. Chemotactic migration of CD16  and CD16  monocytes.
(A) Monocytes were stained with PC5 anti-CD16 mAb and placed in the
upper chamber of transwells. Chemokines were placed in the bottom
chamber. After 2.5 h, CD16  and CD16  monocytes that migrated into
the bottom chamber were counted by FACS®. The IM (mean   SEM,
n   3–8) at optimal chemokine concentrations, 50 ng/ml for MCP-1,
MIP-1 , and SDF-1 , and 10 ng/ml for FKN, is shown. (B) Confluent
pHUVEC and iHUVEC monolayers were analyzed for junction expres-
sion of VE-cadherin,  -catenin, and JAM-1 molecules. Results are repre-
sentative of two independent experiments. (C) Monocytes were assessed
for their ability to cross a confluent iHUVEC monolayer in response to
optimal concentrations of chemokines. After 4 h, CD16  and CD16 
monocytes that migrated into the bottom chamber were counted by
FACS®. The IM (mean   SEM, n   6) is shown. *, P   0.05, Student’s
t test (CD16  vs. CD16  monocytes).T
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Fig. 4 C). Similar results were obtained when monocytes
were perfused over TNF- /IFN- –stimulated pHUVEC
(Fig. S2, available at http://www.jem.org/cgi/content/
full/jem.20022156/DC1). These results demonstrate that
CD16  and CD16  monocytes attach to cytokine-stimu-
lated HUVEC with similar efficiency despite different
levels of CD62L expression and suggest that CX3CR1
preferentially mediates CD16  monocyte attachment to
FKN-expressing endothelial cells.
We further sought to determine whether the CX3CR1
interaction with FKN is required for CD16  monocyte ad-
hesion to endothelial cells. When monocytes were prein-
cubated with soluble FKN, there was a dramatic decrease
in the number of CD16  monocytes arrested onto FKN-
HUVEC, but not ST-HUVEC (Fig. 4 D). Thus,
CX3CR1 is not the only molecule involved in CD16 
monocyte recruitment onto inflamed endothelia. Other
adhesion molecules might compensate for the low expres-
sion of CD62L and contribute to the accumulation of
CD16  monocyte onto endothelial cells. For example,
PSGL-1, which is highly expressed on CD16  monocytes,
may interact with CD62E expressed on cytokine-stimu-
lated endothelial cells (Fig. 4 A, top; reference 18) and
thereby mediate CD16  monocyte arrest. The demonstra-
tion that CD16  monocytes can arrest onto endothelial
cells in the presence of soluble FKN is consistent with pre-
vious reports demonstrating unaltered monocyte trafficking
in CX3CR1- and FKN-deficient mice (26, 27). Neverthe-
less, recent studies indicate that FKN-mediated monocyte
infiltration plays a critical role in atherosclerotic plaque for-
mation (28, 29), suggesting that monocyte recruitment via
the CX3CR1-FKN pathway can have deleterious conse-
quences in vivo.
In summary, we identified FKN as the major chemo-
kine and adhesion molecule mediating CD16  monocyte
arrest and migration. FKN alone or in combination with
SDF-1  preferentially triggered TEM of CD16  mono-
cytes. In contrast, MCP-1 and MIP-1  were potent che-
mokines for CD16  but not CD16  monocytes. Con-
sistent with their high CX3CR1 expression, CD16 
monocytes arrested on cell surface–expressed FKN under
flow with higher frequency compared with CD16  mono-
cytes. These findings suggest that CD16   monocytes
might be preferentially recruited into anatomic sites ex-
pressing FKN. Taking into account our results and those
recently reported by other groups (28, 29), we propose
that CD16  monocytes might be preferentially recruited
to the vessel wall via locally expressed FKN and play an
important role in atherosclerotic lesion formation. Fur-
thermore, CD16  monocytes might be recruited into the
brain of AIDS patients expressing high levels of FKN and
SDF-1 (22, 30), and mediate blood-brain barrier damage
and neuronal injury in HIV-associated dementia via their
release of proinflammatory cytokines (3, 5) and neurotoxic
factors (4). Understanding mechanisms of CD16  mono-
cyte trafficking and the functional role of these cells in
pathological conditions may suggest new therapeutic strat-
egies to prevent deleterious consequences of monocyte in-
filtration to sites of chronic inflammation.
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Figure 4. Firm arrest of CD16  monocytes onto endothelial cells un-
der flow. (A) iHUVEC were incubated with 40 ng/ml TNF-  and 50
ng/ml IFN-  (ST-HUVEC) for 5 h (top) or transfected to stably express
FKN (bottom, KN-HUVEC). Cells were harvested, stained with anti-
CD62E, anti–VCAM-1, and anti-FKN mAbs, and analyzed by FACS®.
Results are representative of three independent experiments. (B) Mono-
cytes were labeled with FITC anti-CD16 mAb and perfused over unstim-
ulated (NS-HUVEC), ST-HUVEC, and FKN-HUVEC monolayers at
0.5 dynes/cm2 flow rate. The number of total monocytes arrested onto
endothelial cells (mean   SD, n   4) is shown. *, P   0.05, Student’s t
test (FKN-HUVEC or ST-HUVEC vs. NS-HUVEC). (C) The percent-
age of CD16  monocytes in the input fraction was compared with that in
the fraction arrested onto FKN-HUVEC and ST-HUVEC (mean   SD,
n   4). *, P   0.05, Student’s t test (arrested vs. input fraction). (D)
Monocytes were incubated with soluble FKN (1  g/106 cells for 10 min
at 4 C) and perfused over FKN-HUVEC and ST-HUVEC. Results are
representative of two experiments performed with monocytes from dif-
ferent donors.T
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